Home World News Daraxonrasib Shows Antitumour Activity in Patients with Previously Treated Metastatic RAS-mutated NSCLC World News Daraxonrasib Shows Antitumour Activity in Patients with Previously Treated Metastatic RAS-mutated NSCLC By Ogkologos - September 10, 2026 111 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in... April 10, 2024 ESMO Targeted Anticancer Therapies Congress 2023 February 24, 2023 Thinking outside the chromosome – how ecDNA is challenging conventional thinking November 11, 2022 Physicians Debate Recent FDA Approval of an Immune Checkpoint Inhibitor in... March 31, 2021 Load more HOT NEWS Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and... Our 10 top tips to help you talk about cancer Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described Addressing Common Concerns Around Taking Opioids for Cancer-Related Pain: An Expert...
